Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health

Inclusion: * Good general health * ≥18 years of age on the day of screening and are ≤50 years of age on the day of IP administration * Adherence to the requirements of the protocol and the follow-up for the planned duration of the study * Undergo HIV testing, risk reduction counseling, and receive HIV test results * As applicable use male or female condoms for 1 month following IP administration * Use an effective method of contraception from at least 2 weeks before and continue until 3 months following receipt of vaccine * As applicable undergo urine pregnancy tests * Forgo donation of blood or any other tissues throughout the course of the study Exclusion: * Any clinically relevant abnormality * Any clinically significant acute or chronical medical condition * Women who are pregnant or breastfeeding * Bleeding disorder * Infectious disease * History of splenectomy * Receipt of any vaccine within the previous 28 days or planned receipt within 28 days after vaccination with IP. * Receipt of blood transfusion or blood-derived products within 3 months prior to screening * Prior exposure to SEBOV or history of any hemorrhagic fever * Prior receipt of any VSV-vectored vaccine * Receipt of another IP within 3 months prior to enrollment or expected participation during this study. * Prior receipt of another Sudan Ebola vaccine or receipt of polyclonal or monoclonal antibodies directed against Sudan Ebola in the past 6 months * History of severe reactogenicity to vaccines or severe allergy to food or medications * A history of malignancy in the past 5 years (prior to screening) or ongoing malignancy. * Serious infections requiring antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment * Body mass index (BMI) ≥35 * Current or planned occupational or household contact from screening through 3 months after vaccine administration with any immunocompromised individual